激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后

doi:10.19723/j.issn.1671-167X.2022.05.013

北京大学学报（医学版） ›› 2022, Vol. 54 ›› Issue (5): 853-862. doi: 10.19723/j.issn.1671-167X.2022.05.013

激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后

王跃¹,张爽¹,张虹¹,梁丽¹,徐玲²,程元甲²,段学宁²,刘荫华²,李挺^1,*()

1. 北京大学第一医院病理科，北京 100034
2. 北京大学第一医院乳腺疾病中心，北京 100034

收稿日期:2022-06-22 出版日期:2022-10-18 发布日期:2022-10-14
通讯作者: 李挺 E-mail:lixiaoting12@hotmail.com
作者简介:李挺，北京大学第一医院病理科教授，主任医师，博士生导师。毕业于华西医科大学医学系及病理学系，留学于日本冈山大学癌研生化室、日本大阪大学分子病理系、美国M.D.Anderson癌症中心血液病理学系，曾任日本大阪大学病理系客座教授。现任中国医师病理分会第一、二、三届常委兼秘书长，北京医学会乳腺专委会副主任委员，北京医学会病理专委会乳腺学组长，北京大学医学部临床教学委员会病理学组长、临床病理专业学位点创建及召集人。
专长于多系统疑难病理诊断，尤其在淋巴造血、乳腺及分子病理领域有很深造诣。长期钻研乳腺亚专科病理学，非常熟悉乳腺疾病病理诊断和乳腺癌现代病理学诊断评估等前沿内容，建立并领导北京大学第一医院乳腺疾病中心相关病理专业组工作。先后承担国家自然科学基金(5项)、首都医学发展科研基金(磁共振成像及肿瘤分子标志物检测对乳腺癌新辅助化疗疗效评估及预测的临床研究)、北京市科技计划(乳腺癌患者保留乳房手术影像学证据研究)等各级课题10余项；以第一和责任作者发表论著100余篇，其中SCI收录40余篇。获中华医学科技二等奖、北京市科技二等奖、北京医学科技二等奖
基金资助:
国家重点研发计划(2016YFC0901302)

Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer

Yue WANG¹,Shuang ZHANG¹,Hong ZHANG¹,Li LIANG¹,Ling XU²,Yuan-jia CHENG²,Xue-ning DUAN²,Yin-hua LIU²,Ting LI^1,*()

1. Department of Pathology, Peking University First Hospital, Beijing 100034, China
2. Breast Disease Center, Peking University First Hospital, Beijing 100034, China

Received:2022-06-22 Online:2022-10-18 Published:2022-10-14
Contact: Ting LI E-mail:lixiaoting12@hotmail.com
Supported by:
the National Key R&D Program of China(2016YFC0901302)

摘要/Abstract

摘要：

目的: 探讨激素受体阳性/人表皮生长因子受体2阴性(hormone receptor-positive/human epidermal growth factor receptor 2-negative, HR +/HER2 -)乳腺癌患者临床病理特征及预后。方法: 收集2008年1月至2017年12月北京大学第一医院乳腺疾病中心连续诊治的3 035例浸润性乳腺癌患者，对临床病理信息完善的HR +/HER2 -患者的重要临床病理参数及其预后意义进行分析。结果: 1 920例(63.26%)HR +/HER2 -乳腺癌患者中资料完善者1 624例，其中124例(7.64%)出现复发转移，63例死于该病，5年总生存率和无病生存率分别为93.0%及92.6%。pT1及2期占92.80%，pN0期占69.03%；组织学非特殊型占89.66%，分级1、2、3级分别为30.11%、55.60%和14.29%；ER阴性、低表达、高表达患者分别占1.60%、2.09%、96.31%，PR阴性、低表达、高表达分别占6.83%、10.47%、82.70%；Ki67指数＜10%、≥10%且 < 20%、≥20%者分别占19.52%、32.02%和48.46%。预后及生存分析显示, pT1期复发转移风险较pT3组低，pT2和pT3组较pT1组无病生存期(disease-free survival，DFS)短，易复发转移；pN0、pN1及pN2期复发转移风险均较pN3期低，与DFS呈负相关；组织学1及2级复发转移风险较3级低，与DFS呈负相关；Ki67指数≥20%更易复发转移。ER在HR +/HER2 -乳腺癌中预后意义不明显，但PR阴性和低表达更易复发转移，生存分析显示，PR表达水平＜10%患者的DFS及总生存期(overall survival，OS)最短，10%~60%次之，＞60%最长。124例复发转移者以骨转移多见(55例，44.35%)，而肝转移者(30例，24.20%)预后最差。结论: 本研究表明，pT分期、pN分期、组织学分级、HR表达水平、Ki67指数等临床病理参数是HR +/HER2 -乳腺癌的重要预后因素，但意义有所不同，其中pN分期和组织学分级有独立预后价值，PR阳性表达水平具有重要预后和风险预测价值，随PR表达水平升高(＜10%、10%~60%、＞60%)，DFS及OS递增，复发转移风险递减，PR表达＞60%者DFS及OS最长，复发转移风险最低，PR危险性分层具有独立预后意义。

关键词: 乳腺肿瘤, 肿瘤复发，局部, 肿瘤转移, 受体，孕酮, 受体，雌激素, 人表皮生长因子受体2

Abstract:

Objective: To investigate the clinicopathological features and prognosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 -) breast cancer. Methods: In the study, 3 035 consecutive breast cancer patients diagnosed in Breast Disease Center, Peking University First Hospital from January 2008 to December 2017 were collected. The prognostic signi-ficance of important pathological factors in HR +/HER2 - patients with complete clinicopathological information was analyzed. Results: Within the 1 920 (63.26%) cases of HR +/HER2 - breast cancer, there were 1 624 cases with complete clinicopathological data, of which, 124 cases (7.64%) recurred and/or metastasized and 63 cases died of the disease, and the 5-year overall survival (OS) rate and disease-free survival (DFS) rate was 93.0% and 92.6% respectively. The stage of pT1-2 was 92.80%, while pN0 was 69.03%. 89.66% cases belonged to histologically non-specific type and 30.11%, 55.60%, 14.29% were credited to Grade 1, 2 and 3 respectively. The distribution of ER negative, low or high expression groups were 1.60%, 2.09% and 96.31%, while PR were 6.83%, 10.47%, 82.70%, respectively. The group of Ki67 index < 10% was 19.52%, ≥10% & < 20% for 32.02%, ≥20% for 48.46%. Survival analysis showed that cases with pT1 stage had lower risk of recurrence than those with pT3, while cases with pT2 and pT3 had shorter DFS than those with pT1, with higher risk of recurrence and metastasis. Analysis proved that both pN stage and histological grade were negatively correlated with DFS. The cases with pN0, pN1 and pN2 were lower risk of recurrence than those with pN3, while cases with Grade 1 and 2 had lower risk of recurrence than cases with Grade 3. And the group of Ki67 index ≥20% showed higher risk of recurrence and metastasis. The prognostic significance of ER expression in HR+/HER2- breast cancer was not significant. However, the negative/low PR expression groups showed higher risk of recurrence and metastasis, of which PR < 10% group had shortest DFS and OS, followed by 10%-60% group and then > 60% group. The most common site of metastasis was bone (55 cases, 44.35%), while cases with liver metastasis (30 cases, 24.20%) had the worst outcome. Conclusion: Our study revealed that pT, pN, Grade, HR expression level and Ki67 index were important prognostic factors for HR +/HER2 - breast cancer, although there are variables in prognostic value. Factors of pN and Grade showed independent prognostic significance. PR expression level had prognostic significance for the risk of recurrence and metastasis. The stratified level of PR expression (< 10%, 10%-60%, >60%) had independent prognostic value, showing successively longer DFS and OS, lower risk of recurrence. PR>60% group had the longest DFS and OS as well as the lowest risk of recurrence.

Key words: Breast neoplasms, Neoplasm recurrence, local, Neoplasm metastasis, Receptors, progesterone, Receptors, estrogen, Human epidermal growth factor receptor 2

中图分类号:

R737.9

王跃,张爽,张虹,梁丽,徐玲,程元甲,段学宁,刘荫华,李挺. 激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后[J]. 北京大学学报（医学版）, 2022, 54(5): 853-862.

Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer[J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862.

图/表 9

表1

1 624例HR +/HER2 -乳腺癌的临床病理学特征"

Characteristics	All cases (n=1 624)	Metastasis (n=124)	Non-metastasis (n=1 500)
Age/years	54 (21-92)	55 (22-90)	54 (21-92)
Gender
Female	1 609 (99.08)	122 (98.39)	1 487 (99.13)
Male	15 (0.92)	2 (1.61)	13 (0.87)
Family history
Yes	57 (3.51)	3 (2.42)	54 (3.60)
No	1 567 (96.49)	121 (97.58)	1 446 (96.40)
Menopausal status^a
Premenopausal	562 (34.93)	41 (33.61)	521 (35.04)
Postmenopausal	1 047 (65.07)	81 (66.39)	966 (64.96)
Surgery
Breast-conserving surgery	460 (28.33)	26 (20.97)	434 (28.93)
Mastectomy	1 164 (71.67)	98 (79.03)	1 066 (71.07)
Histologictype
NOS	1 456 (89.66)	111 (89.52)	1 342 (89.47)
ILC	69 (4.25)	9 (7.26)	60 (4.00)
Mucinous carcinoma	69 (4.25)	0	69 (4.60)
Others^b	30 (1.84)	4 (3.23)	29 (1.93)
pT stage
1	913 (56.22)	54 (43.55)	859 (57.27)
2	594 (36.58)	57 (45.97)	537 (35.80)
3	117 (7.20)	13 (10.48)	104 (6.93)
pN stage
0	1 121 (69.03)	51 (41.13)	1 070 (71.33)
1	414 (25.49)	35 (28.23)	379 (25.27)
2	52 (3.20)	17 (13.71)	35 (2.33)
3	37 (2.28)	21 (16.93)	16 (1.07)
Grade
1	489 (30.11)	24 (19.36)	465 (31.00)
2	903 (55.60)	64 (51.61)	839 (55.93)
3	232 (14.29)	36 (29.03)	196 (13.07)
ER
＜1%	26 (1.60)	3 (2.42)	23 (1.53)
1%-10%	34 (2.09)	4 (3.23)	30 (2.00)
>10%	1 564 (96.31)	117 (94.35)	1 447 (96.47)
PR
＜1%	111 (6.84)	11 (8.87)	100 (6.67)
1%-10%	170 (10.47)	19 (15.32)	151 (10.07)
11%-60%	301 (18.53)	33 (26.61)	268 (17.86)
>60%	1 042 (64.16)	61 (49.19)	981 (65.40)
HR status
ER+/PR+	1 487 (91.57)	110 (88.71)	1 377 (91.80)
ER+/PR-	111 (6.83)	11 (8.87)	100 (6.67)
ER-/PR+	26 (1.60)	3 (2.42)	23 (1.53)
HER2
0	634 (39.04)	49 (39.52)	585 (39.00)
1+	612 (37.68)	44 (35.48)	568 (37.87)
2+，FISH-	378 (23.28)	31 (25.00)	347 (23.13)
Ki67
＜10%	317 (19.52)	20 (16.13)	297 (19.80)
≥10%&<20%	520 (32.02)	24 (19.35)	496 (33.07)
≥20%	787 (48.46)	80 (64.52)	707 (47.13)
Molecular subtype
Luminal A	516 (31.77)	44 (35.48)	472 (31.47)
Luminal B	1 108 (68.23)	80 (64.52)	1 028 (68.53)
Endocrine therapy^c
No	11 (0.68)	3 (2.42)	8 (0.53)
Preoperative	9 (0.55)	1 (0.81)	8 (0.53)
Postoperative	1 609 (99.07)	120 (96.77)	1 489 (99.27)
Neoadjuvant chemotherapy
No	1 392 (85.71)	93 (75.00)	1 299 (86.60)
Yes	232 (14.29)	31 (25.00)	201 (13.40)
Adjuvant chemotherapy
No	947 (58.31)	36 (29.03)	911 (60.73)
Yes	677 (41.69)	88 (70.97)	589 (39.27)

表1

图1

表2

图2

图3

图4

图5

表3

图6

参考文献 23

1	Cao W , Chen HD , Yu YW , et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134 (7): 783- 791. doi: 10.1097/CM9.0000000000001474
2	Wolff AC , Hammond ME , Schwartz JN , et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. J Clin Oncol, 2007, 25 (1): 118- 145. doi: 10.1200/JCO.2006.09.2775
3	WHO Classification of Tumours Editorial Board . WHO classification of tumours[M]. 5th ed Lyon: IARC Press, 2019.
4	Amin MB , Edge SB , Greene FL , et al. AJCC cancer staging ma-nual[M]. 8th ed New York: Springer, 2017.
5	Goldhirsch A , Wood WC , Coates AS , et al. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 22 (8): 1736- 1747. doi: 10.1093/annonc/mdr304
6	Hammond ME , Hayes DF , Dowsett M , et al. American Society of Clinical Oncology/College of American Pathologists guideline re-commendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28 (16): 2784- 2795. doi: 10.1200/JCO.2009.25.6529
7	Wolff AC , Hammond ME , Hicks DG , et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Patho-logists clinical practice guideline update[J]. Arch Pathol Lab Med, 2014, 138 (2): 241- 256. doi: 10.5858/arpa.2013-0953-SA
8	Cheang MC , Chia SK , Voduc D , et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer[J]. J Nat Cancer Inst, 2009, 101 (10): 731- 750.
9	Wolff AC , Hammond MEH , Allison KH , et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update[J]. J Clin Oncol, 2018, 36 (20): 2105- 2122. doi: 10.1200/JCO.2018.77.8738
10	李挺. 乳腺癌异质性的分子遗传学基础及临床应用[J]. 中华外科杂志, 2017, 55 (2): 104- 108. doi: 10.3760/cma.j.issn.0529-5815.2017.02.006
11	李挺. 乳腺癌病理诊断评估与治疗决策[J]. 中国实用外科杂志, 2008, 28 (7): 74- 76.
12	Perou CM , Sorlie T , Eisen MB , et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406 (6797): 747- 752. doi: 10.1038/35021093
13	Zhang S , Huang S , Zhang H , et al. Histo-and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China: Evidences on necessity of histological subtyping and grading[J]. Chin J Cancer Res, 2020, 32 (5): 580- 595.
14	André F , Ciruelos E , Rubovszky G , et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer[J]. N Engl J Med, 2019, 380 (20): 1929- 1940. doi: 10.1056/NEJMoa1813904
15	van't Veer LJ , Dai H , van de Vijver MJ , et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415 (6871): 530- 536. doi: 10.1038/415530a
16	Sparano JA , Crager MR , Tang G , et al. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer[J]. J Clin Oncol, 2021, 39 (6): 557- 564. doi: 10.1200/JCO.20.03007
17	Pan H , Gray R , Braybrooke J , et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med, 2017, 377 (19): 1836- 1846. doi: 10.1056/NEJMoa1701830
18	Duffy MJ , Harbeck N , Nap M , et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)[J]. Eur J Cancer, 2017, 75, 284- 298. doi: 10.1016/j.ejca.2017.01.017
19	Zhao H , Gong Y . The prognosis of single hormone receptor-positive breast cancer stratified by HER2 status[J]. Front Oncol, 2021, 11, 643956. doi: 10.3389/fonc.2021.643956
20	Dauphine C , Moazzez A , Neal J , et al. Single hormone receptor-positive breast cancers have distinct characteristics and survival[J]. Ann Surg Oncol, 2020, 27 (12): 4687- 4694. doi: 10.1245/s10434-020-08898-5
21	Li Z , Tu Y , Wu Q , et al. Clinical characteristics and outcomes of single versus double hormone receptor-positive breast cancer in 2 large databases[J]. Clin Breast Cancer, 2020, 20 (2): e151- e163. doi: 10.1016/j.clbc.2019.07.002
22	Ye J , Wang W , Xin L , et al. The clinicopathological factors associated with disease progression in luminal A breast cancer and characteristics of metastasis: A retrospective study from a single center in China[J]. Anticancer Res, 2017, 37 (8): 4549- 4556.
23	Yamamura J , Kamigaki S , Fujita J , et al. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: A multicenter study of 271 patients[J]. BMC Cancer, 2021, 21 (1): 476. doi: 10.1186/s12885-021-08219-3

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Variables	Univariate		Multivariate
Variables	HR (95%CI)	P value	HR (95%CI)	P value
pT stage
1	0.507 (0.276-0.928)	0.028		0.895
2	0.822 (0.450-1.501)	0.523		0.850
3	1.0 (reference)
pN stage
0	0.070 (0.042-0.117)	＜0.001	0.081 (0.049-0.136)	＜0.001
1	0.168 (0.098-0.289)	＜0.001	0.162 (0.093-0.280)	＜0.001
2	0.427 (0.225-0.811)	0.009	0.472 (0.246-0.904)	0.024
3	1.0 (reference)		1.0 (reference)
Grade
1	0.258 (0.154-0.432)	＜0.001	0.327 (0.191-0.560)	＜0.001
2	0.398 (0.265-0.599)	＜0.001	0.472 (0.311-0.717)	＜0.001
3	1.0 (reference)		1.0 (reference)
ER
＜1%	1.069 (0.339-3.369)	0.909		0.795
1%-10%	1.250 (0.461-3.390)	0.661		0.675
>10%	1.0 (reference)
PR
＜10%	2.469 (1.592-3.830)	＜0.001	1.949 (1.247-3.047)	0.003
10%-60%	1.970 (1.290-3.009)	0.002	1.724 (1.120-2.654)	0.013
>60%	1.0 (reference)		1.0 (reference)
HER2
0	0.793 (0.505-1.244)	0.313		0.530
1+	0.802 (0.506-1.270)	0.347		0.398
2+，FISH-	1.0 (reference)
Ki67
＜10%	0.486 (0.298-0.795)	0.004		0.634
≥10%&<20%	0.435 (0.276-0.687)	＜0.001		0.341
≥20%	1.0 (reference)
Endocrine therapy
No	0.242 (0.077-0.761)	0.015	3.221 (0.991-10.466)	0.052
Yes	1.0 (reference)		1.0 (reference)
Neoadjuvant chemotherapy
No	0.620 (0.412-0.932)	0.022		0.214
Yes	1.0 (reference)

Variables	HR+/HER2- breast cancer				HR+/HER2- breast cancer with relapse
Variables	ER+/PR+ (n=1 487)	ER+/PR- (n=111)	ER-/PR+ (n=26)	P	ER+/PR+ (n=110)	ER+/PR- (n=11)	ER-/PR+ (n=3)	P
Menopausal status^a				＜0.001				0.038
Premenopausal	531 (36.05)	17 (15.45)	14 (53.85)		36 (33.33)	2 (18.18)	3 (100.00)
Postmenopausal	942 (63.95)	93 (84.55)	12 (46.15)		72 (66.67)	9 (81.82)	0
pT stage				0.555				0.993
1	836 (56.22)	60 (54.05)	17 (65.38)		49 (44.54)	4 (36.36)	1 (33.33)
2	543 (36.52)	43 (38.74)	8 (30.77)		48 (43.64)	7 (63.64)	2 (66.67)
3	108 (7.26)	8 (7.21)	1 (3.85)		13 (11.82)	0	0
pN stage				0.042				0.781
0	1 036 (69.67)	65 (58.56)	20 (76.92)		45 (40.91)	4 (36.36)	2 (66.67)
1-3	451 (30.33)	46 (41.44)	6 (23.08)		65 (59.09)	7 (63.64)	1 (33.33)
Grade				＜0.001				0.948
1	457 (30.73)	28 (25.23)	4 (15.38)		22 (20.00)	2 (18.18)	0
2	840 (56.49)	54 (48.65)	9 (34.62)		55 (50.00)	6 (54.55)	3 (100.00)
3	190 (12.78)	29 (26.12)	13 (50.00)		33 (30.00)	3 (27.27)	0
Ki67				＜0.001				0.669
＜10%	303 (20.38)	10 (9.01)	4 (15.38)		19 (17.27)	0	1 (33.33)
≥10%&<20%	487 (32.75)	33 (29.73)	0		21 (19.09)	3 (27.27)	0
≥20%	697 (46.87)	68 (61.26)	22 (84.62)		70 (63.64)	8 (72.73)	2 (66.67)
Molecular subtype				＜0.001				0.016
Luminal A	501 (33.69)	11 (9.91)	4 (15.38)		43 (39.09)	0	1 (33.33)
Luminal B	986 (66.31)	100 (90.09)	22 (84.62)		67 (60.91)	11 (100.00)	2 (66.67)

[1]	朱晓娟,张虹,张爽,李东,李鑫,徐玲,李挺. 人表皮生长因子受体2低表达乳腺癌的临床病理学特征及预后[J]. 北京大学学报（医学版）, 2023, 55(2): 243-253.
[2]	宋国红,李惠平,邸立军,严颖,姜晗昉,徐玲,万冬桂,李瑛,王墨培,肖宇,张如艳,冉然,王环. 真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性[J]. 北京大学学报（医学版）, 2020, 52(2): 254-260.
[3]	张晔,张妮,刘晓筱,周传香. 唾液腺腺样囊性癌淋巴结转移相关的临床病理分析[J]. 北京大学学报（医学版）, 2020, 52(1): 30-34.
[4]	张旭初,张建华,王荣福,范岩,付占立,闫平,赵光宇,白艳霞. ¹⁸F-FDG PET/CT联合多种肿瘤标志物在结直肠中分化腺癌术后复发及转移中的应用价值[J]. 北京大学学报（医学版）, 2019, 51(6): 1071-1077.
[5]	黄子雄，杜依青，张晓鹏，刘士军，徐涛. 肾细胞癌骨转移的临床与病理分析[J]. 北京大学学报(医学版), 2018, 50(5): 811-815.
[6]	黄子雄，张晓鹏，董森，刘士军，杨荣利，周宇石，马伟国. 肾黏液性小管和梭形细胞癌合并骨转移1例及文献回顾[J]. 北京大学学报(医学版), 2018, 50(4): 732-735.
[7]	朱燕，石永进，赵玉亮，朱平. 拓扑异构酶抑制剂通过ATM/ATR和NF-κB途径上调乳腺癌细胞MICA/B 的表达[J]. 北京大学学报(医学版), 2018, 50(2): 318-325.
[8]	康磊，霍焱，王荣福，张春丽，闫平，徐小洁. MicroRNA-155靶向的放射性标记探针对乳腺癌小鼠模型的活体显像[J]. 北京大学学报(医学版), 2018, 50(2): 326-330.
[9]	赵轶国，杨晓东，张雁凯，宁宁，邢兆东，叶颖江. 美克尔憩室癌变及肝多发转移并消化道出血1例[J]. 北京大学学报(医学版), 2017, 49(6): 1095-1097.
[10]	郭福新，姜玉良，吉喆，彭冉，孙海涛，王俊杰. 3D打印非共面模板辅助CT引导125Ⅰ粒子植入治疗锁骨上复发转移癌的剂量学研究[J]. 北京大学学报(医学版), 2017, 49(3): 506-511.
[11]	王威，郑磊，刘树铭，黄明伟，石妍，吕晓鸣，张杰，张建国. 单纯放射性粒子治疗后的头颈部腺源性癌远处转移[J]. 北京大学学报(医学版), 2017, 49(3): 547-550.
[12]	方伟岗，田新霞. 肿瘤微环境中一种新型促侵袭因子的发现——细胞外ATP功能及机制的研究进展[J]. 北京大学学报(医学版), 2017, 49(2): 188-195.
[13]	李秀楠，刘爱蕙，唐欣，任宇. 尿路上皮癌相关1基因通过竞争性抑制miR-18a增强乳腺癌细胞的他莫昔芬治疗耐药[J]. 北京大学学报(医学版), 2017, 49(2): 295-302.
[14]	邢云超，熊耕砚，方东，张争，蔡林，张雷，何志嵩，李学松，周利群. 上尿路尿路上皮癌术前预后相关因素分析及初步风险分层模型构建[J]. 北京大学学报(医学版), 2016, 48(6): 1032-1037.
[15]	董颖，周梅，巴晓军，司婧文，李文婷，王颖，李东，李挺. 子宫内膜癌中DNA甲基转移酶3B的表达特点与临床意义[J]. 北京大学学报(医学版), 2016, 48(5): 788-794.

激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后

Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer

RICH HTML

PDF (PC)

摘要/Abstract

引用本文

使用本文

图/表 9

参考文献 23

相关文章 15

Metrics

本文评价

推荐阅读 10